- Home
- STX vs UTHR Comparison
STX vs UTHR Comparison
Compare STX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STX
- UTHR
- Stock Information
- Founded
- STX 1978
- UTHR 1996
- Country
- STX Singapore
- UTHR United States
- Employees
- STX N/A
- UTHR N/A
- Industry
- STX Electronic Components
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- STX Technology
- UTHR Health Care
- Exchange
- STX Nasdaq
- UTHR Nasdaq
- Market Cap
- STX 18.7B
- UTHR 16.1B
- IPO Year
- STX 2002
- UTHR 1999
- Fundamental
- Price
- STX $108.19
- UTHR $370.83
- Analyst Decision
- STX Buy
- UTHR Buy
- Analyst Count
- STX 20
- UTHR 14
- Target Price
- STX $122.95
- UTHR $378.36
- AVG Volume (30 Days)
- STX 3.1M
- UTHR 268.1K
- Earning Date
- STX 01-21-2025
- UTHR 02-19-2025
- Dividend Yield
- STX 2.66%
- UTHR N/A
- EPS Growth
- STX N/A
- UTHR 25.10
- EPS
- STX 5.45
- UTHR 22.72
- Revenue
- STX $8,035,000,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- STX $42.22
- UTHR $26.19
- Revenue Next Year
- STX $13.36
- UTHR $10.79
- P/E Ratio
- STX $19.84
- UTHR $16.45
- Revenue Growth
- STX 24.17
- UTHR 25.04
- 52 Week Low
- STX $82.31
- UTHR $208.62
- 52 Week High
- STX $115.32
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- STX 79.60
- UTHR 55.32
- Support Level
- STX $86.64
- UTHR $357.25
- Resistance Level
- STX $111.91
- UTHR $372.34
- Average True Range (ATR)
- STX 2.72
- UTHR 8.53
- MACD
- STX 2.59
- UTHR 1.49
- Stochastic Oscillator
- STX 85.28
- UTHR 80.54
About STX Seagate Technology Holdings PLC (Ireland)
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.